Sources: smart ring maker Oura and some of its backers seek to raise up to $3B in a US IPO that could take place as soon as September and value it at over $16B
Oura Health Oy, a maker of smart rings that track health, fitness and sleep, and some of its backers are seeking to raise …
Context & Ripple Effects
Oura's path to this point is unusually fast: from a $28M Series B in 2020, to an $875M+ Series E at $10.9B in September 2025, then confidential US IPO paperwork filed in May 2026 for a listing later in the year. Sources now say the company and some of its backers are targeting up to $3B raised and a valuation above $16B — roughly 50% above the Series E mark — with September floated as the earliest window.
The acceleration cuts against the company's own recent signal: in January, sources reported Oura planned a discounted tender offer for early investors explicitly aimed at staying private longer. The rumored IPO would instead hand those same early holders a public exit months later, while Whoop's own reported IPO ambitions keep the category's two leading names on parallel tracks toward public markets.
First-order effects
- Backers selling in the offering get their first real liquidity after a run that saw Oura's valuation climb from $2.55B in 2022 to $10.9B by late 2025, with the rumored $16B+ target implying another step-up of nearly half again.
- A September debut would land Oura in public markets just weeks after the Ring 5's June launch at $399 — a price increase from the Ring 4's $349 — meaning its first quarterly reports will immediately test whether premium hardware pricing holds.
Second-order effects
- Whoop, already reported to be eyeing an IPO at a high valuation, faces pressure to match Oura's timeline and pricing benchmark, since the first wearable-health company through the door sets the multiple the market applies to both.
- Public-listing disclosure requirements will force Oura to break out unit economics — rings sold, subscription attach, returns — that rivals and retail partners have so far only seen filtered through funding-round narratives.
Third-order effects
- If Oura lists successfully above $16B, the consumer health-wearables category shifts from venture-funded private growth stories to a public-market sector with disclosed margins, resetting how startups like it are priced and how long investors expect them to stay private.
- Reviewer concerns around the Ring 5's durability and thin upgrade incentives suggest the public Oura will need to defend recurring-revenue quality rather than hardware novelty — pushing the category's competition toward software and services differentiation.
The trend: Consumer health-wearables leaders are racing from mega private rounds to public listings, with each debut setting the valuation template for the rest of the category.